VANCOUVER, BC, September 27, 2018 – VANC Pharmaceuticals Inc. (“VANC”) has contracted with Lampyon Canada Inc. to extend VANC’s proprietary education and ecommerce portal, the Corozon Platform (www.corozonplatform.com), with medical cannabis education and new sales capabilities. Corozon Platform, which is derived from the Latin word for heart, is designed to be the central educational and […]
VANCOUVER, BC, September 17, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) is pleased to announce the appointment of Philippe Ugnat as Strategic Advisor to help drive the corporate growth and strengthen the Company’s presence in the Province of Ontario and Québec. Upon joining VANC as Strategic Advisor, Philippe said: “I’m excited to be […]
VANCOUVER, BC, September 17, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) is pleased to announce the appointment of Ms. Zula Kropivnitski as its Chief Financial Officer (“CFO”). Ms. Kropivnitski is a certified public accountant, CGA with over 10 years of public company experience. She acts as the CFO of public companies with a […]
July 30, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) (TSXV: VANC, OTCQB: NUVPF) is pleased to announce that further to its news release dated July 11, 2018, it has closed a non-brokered private placement of 5,327,335 units (“Units”) of the Company at a price of $0.15 per Unit for gross proceeds of approximately […]
July 11, 2018 – VANC Pharmaceuticals Inc. (“VANC”), announced today a non-brokered private placement of up to 6,666,666 units at a price of $0.15 per unit for gross proceeds of up to $1,000,000 (the “Offering”). Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder […]
VANCOUVER, BC, June 21, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) announces that it has issued a total of 182,992 common shares of the Company to Lampyon Canada Inc., in consideration for services rendered pursuant to the terms of a Service Agreement entered into with VANC on April 10th, 2018. The common shares […]
VANC receives PAAB approval for Hema-Fer detail aid VANC receives ASC approval for and launches Hema-Fer website (www.hemafer.ca) VANC launches Amazon Canada online store VANCOUVER, BC, June 5, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is pleased to announce the launch of the Amazon Canada online store for Hema-Fer, along with Pharmaceutical Advertising Advisory Board (PAAB) […]
VANC executes supply and distribution agreement with Emerald VANC issues warrants to Emerald VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) — VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC […]
VANC Pharmaceuticals Inc. (“VANC”) is pleased to announce it has entered into a defintive agreement with Corozon Consulting Corporation (“Corozon Consulting”) for the acquisition of the Corozon Platform (“Platform”). The Platform (www.corozonplatform.com) is an innovative portal designed to provide front line community pharmacists with the knowledge and tools to implement practice change and enhance their […]
VANC Pharmaceuticals Inc. (“VANC”) is pleased to announce that it has selected and entered into a service agreement with Lampyon Canada Inc. (“Lampyon”) as its marketing and creative agency of record, responsible for market research, branding, marketing, communications and creative services. Lampyon will drive branding and communications as VANC is about to start a new […]
